SUN PHARMACEUTICAL INDUSTRIES
Sun Pharmaceutical Industries Performance
52 Week Range
- Open Price
- Previous Close
Start SIP in SUN PHARMACEUTICAL INDUSTRIESStart SIP
Sun Pharmaceutical Industries Share Price
Sun Pharmaceutical Industries Investment Rating
Sun Pharm.Industries has an operating revenue of Rs. 41,023.86 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 12% is healthy, ROE of 6% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 14% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 29 which is a POOR score indicating inconsistency in earnings, a RS Rating of 69 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
|Indicator||Sep 2022||Jun 2022||Mar 2022||Dec 2021||Sep 2021||Jun 2021||Mar 2021|
|Oper Rev Qtr Cr||5,285||4,862||3,988||3,771||4,143||3,313||3,119|
|Operating Expenses Qtr Cr||3,622||3,483||3,007||3,114||3,279||2,694||2,479|
|Operating Profit Qtr Cr||1,663||1,450||1,000||656||864||631||680|
|Depreciation Qtr Cr||384||375||354||355||334||151||152|
|Interest Qtr Cr||93||87||91||85||104||106||103|
|Tax Qtr Cr||15||25||486||5||-98||13||44|
|Net Profit Qtr Cr||1,213||1,012||-1,286||515||809||419||327|
Sun Pharmaceutical Industries Technicals
EMA & SMA
- Bullish Moving Average
- Bearish Moving Average
- 20 Day
- 50 Day
- 100 Day
- 200 Day
- 20 Day
- 50 Day
- 100 Day
- 200 Day
Sun Pharmaceutical Industries Resistance and Support
|MACD Single Line||14.37|
Sun Pharmaceutical Industries Delivery and Volume
|Period||NSE + BSE Volume Avg||NSE + BSE Delivery Volume Avg||NSE + BSE Delivery Volume %|
Sun Pharmaceutical Industries Result Highlights
Sun Pharmaceutical Industries Synopsis
NSE-Medical-Generic DrugsSun Pharma. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 15585.98 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2022. Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050.
|Shares in Float||110.37|
|No of funds||1015|
|U/D Vol ratio||1.2|
|LTDebt / Equity||20|
Sun Pharmaceutical Industries
|Foreign Portfolio Investors||16%||14.95%||14.44%|
|Financial Institutions/ Banks||0.02%||0.22%||0.37%|
Sun Pharmaceutical Industries Management
|Mr. Israel Makov||Chairman, Non Ind & Non Exe Director|
|Mr. Dilip S Shanghvi||Managing Director|
|Mr. Sailesh T Desai||Whole Time Director|
|Mr. Kalyanasundaram Subramanian||Whole Time Director|
|Mr. Sudhir V Valia||Non Exe.Non Ind.Director|
|Dr. Pawan Goenka||Non Exe. & Ind. Director|
|Mr. Rama Bijapurkar||Non Exe. & Ind. Director|
|Mr. Gautam Doshi||Ind. Non-Executive Director|
Sun Pharmaceutical Industries Forecast
Sun Pharmaceutical Industries Corporate Action
|2022-05-30||Audited Results & Final Dividend|
|2022-01-31||Quarterly Results & Interim Dividend|
|2022-08-22||FINAL||Rs.3.00 per share(300%)Final Dividend|
|2022-02-10||INTERIM||Rs.7.00 per share(700%)Interim Dividend|
|2021-02-10||INTERIM||Rs.5.50 per share(550%)Interim Dividend|
Sun Pharmaceutical Industries FAQs
What is Share Price of Sun Pharmaceutical Industries ?
Sun Pharmaceutical Industries share price is ₹1049 As on 29 November, 2022 | 19:17
What is the Market Cap of Sun Pharmaceutical Industries ?
The Market Cap of Sun Pharmaceutical Industries is ₹251894.2 Cr As on 29 November, 2022 | 19:17
What is the P/E ratio of Sun Pharmaceutical Industries ?
The P/E ratio of Sun Pharmaceutical Industries is 61.4 As on 29 November, 2022 | 19:17
What is the PB ratio of Sun Pharmaceutical Industries ?
The PB ratio of Sun Pharmaceutical Industries is 4.9 As on 29 November, 2022 | 19:17
What is the future of Sun Pharmaceutical Industries (Sun Pharma)?
Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD
Who is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma)?
Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).
What is the ROE of Sun Pharmaceutical Industries (Sun Pharma)?
The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.
Is Sun Pharmaceutical Industries (Sun Pharma) Debt to Equity Ratio?
Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.
What is the PE ratio of Sun Pharmaceutical Industries (Sun Pharma)?
The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.